Showing 4871-4880 of 7936 results for "".
- Acne Cure Alliance Announces Call for Dermatologist to Lead Integrative Acne Treatment and Research Centerhttps://practicaldermatology.com/news/20140626-acne_cure_alliance_announces_call_for_dermatologist_to_lead_integrative_acne_treatment_and_research_center/2459187/The Acne Cure Alliance, a non-profit foundation, is actively recruiting a visionary acne expert to lead the Acne Treatment and Research Center - a new and unique integrative practice approach for acne patients. This is an opportunity for a Board-certified dermatologist to join the Board of D
- Jan Marini Skin Research Marks 20 Years of Innovationhttps://practicaldermatology.com/news/20140625-jan_marini_skin_research_marks_20_years_of_innovation/2459188/After 20 years, Jan Marini Skin Research (JMSR) continues to distinguish itself as a recognized leader in the professional skincare industry through its combined focus on results, new productinnovation and its commitment to clinical and medical validation. Robert Weiss, MD, conducted a st
- FDA Issues Guidance Supporting the Responsible Development of Nanotechnology Productshttps://practicaldermatology.com/news/20140625-fda_issues_guidance_supporting_the_responsible_development_of_nanotechnology_products/2459190/Three final guidances and one draft guidance were issued by the U.S. Food and Drug Administration providing greater regulatory clarity for industry on the use of nanotechnology in FDA-regulated products. Nanotechnology is an emerging technology allowing scientists to create, explore, and
- FDA Approves Sivextro to Treat Skin Infections in Adultshttps://practicaldermatology.com/news/20140624-fda_approves_sivextro_to_treat_skin_infections_in_adults/2459192/The FDA approved Sivextro (tedizolid phosphate), a new antibacterial drug, to treat adults with skin infections. Sivextro, which is marketed by Cubist Pharmaceuticals, is approved to treat patients with acute bacterial skin and skin structure infections (ABSSSI) caused by certain susceptible bact
- Verisante Technology, Inc. Announces 2014 First Quarter Results and Provides Operational Updatehttps://practicaldermatology.com/news/20140623-verisante_technology_inc_announces_2014_first_quarter_results_and_provides_operational_update/2459195/Verisante Technology, Inc. (TSX-V: VRS, OTCQX: VRSEF) (the “Company” or “Verisante”), a leader in cancer detection technology, announced today that the Company has released its financial results for the first quarter ended March 31, 2014 .
- Verisante Technology, Inc. Partners with the BC Cancer Foundation to Showcase Aura™ for Skin Cancer Detectionhttps://practicaldermatology.com/news/20140623-verisante_technology_inc_partners_with_the_bc_cancer_foundation_to_showcase_aura_for_skin_cancer_detection/2459196/Verisante Technology, Inc. is partnering with the BC Cancer Foundation to showcase Verisante Aura™, a device for the detection of skin cancer. Verisante has placed an Aura™ at the Foundation's Provincial Office in Vancouver for display and educa
- AAD Issues Statement on Sunscreen Use and Melanoma Riskhttps://practicaldermatology.com/news/20140623-aad_issues_statement_on_sunscreen_use_and_melanoma_risk/2459197/American Academy of Dermatology (AAD) President Brett M. Coldiron, MD, FAAD issued a statement about sunscreen use and melanoma in response to a study that was recently published in the journal Nature.
- Sente, Inc. Awarded European Patent for Active Ingredient in Proprietary Dermal Repair Creamhttps://practicaldermatology.com/news/20140619-sente_inc_awarded_european_patent_for_active_ingredient_in_proprietary_dermal_repair_cream/2459199/Sente has been granted the European Patent for use of a low molecular weight heparan sulfate (HS) for cosmetic products. HS is the most biologically active glycoprotein that is present in all layers of human skin and is the scientific base to Sente Inc's proprietary Dermal Repair Cream. M
- Celsus Therapeutics Receives Ministry of Health of Israel Approval to Conduct Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patientshttps://practicaldermatology.com/news/20140617-a_new_class_of_treatment_can_to_be_used_for_atopic_dermatitis/2459202/Celsus Therapeutics Plc received approval from Ministry of Health of Israel for Phase II Trial of MRX-6 in Pediatric Atopic Dermatitis Patients. The Company plans to conduct the study in five to six centers in Israel as well as Argentina. They plan to enroll 80 pediatric patient
- Allergan Reiterates its Belief that Valeant's Business Model is Unsustainablehttps://practicaldermatology.com/news/20140616-allergan_reiterates_its_belief_that_valeants_business_model_is_unsustainable/2459204/Allergan, Inc. (NYSE: AGN) ("Allergan" or the "Company") today reiterated the Company's concern regarding Valeant Pharmaceuticals International, Inc.'s ("Valeant") unsustainable business model, which relies on serial acquisitions and cost reductions, as opposed to top-line revenue growth and operati